A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of TAK-169 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Condition:   Relapsed and/or Refractory Multiple Myeloma Intervention:   Drug: TAK-169 Sponsor:   Millennium Pharmaceuticals, Inc. Not yet recruiting

Source: ClinicalTrials.gov - July 12, 2019 Category: Research Source Type: clinical trials